Mandelia Ashish has filed 46 insider transactions across 1 company since January 2024.
Most recent transaction: a disposition of 310 shares of Mersana Therapeutics, Inc. ($MRSN) on January 06, 2026.
Activity breakdown: 0 open-market purchases and 6 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 310 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 44 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.00% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 555 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 2870 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.06% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 1312 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.03% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 1687 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.03% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | U | Common Stock | 2300 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.05% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Restricted Stock Units | 666 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Restricted Stock Units | 500 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Restricted Stock Units | 212 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.00% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Restricted Stock Units | 192 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.00% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 1842 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.04% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 1157 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 1183 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 722 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 788 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 359 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | D | Stock Option (right to buy) | 773 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 4519 | $0.00 | 56,907.0000 | 0 | 8.63% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 4166 | $0.00 | 61,073.0000 | 0 | 7.32% | 0.00% |
| Jan. 16, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | S | Common Stock | 3554 | $0.58 | 57,519.0000 | 0 | 5.82% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 4519 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 4166 | $0.00 | 12,501.0000 | 0 | 25.00% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | A | Restricted Stock Unit | 16667 | $0.00 | 16,667.0000 | 0 | 9999.99% | 0.00% |
| Jan. 14, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 4783 | $0.00 | 4,783.0000 | 0 | 50.00% | 0.00% |
| Jan. 14, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 4783 | $0.00 | 54,179.0000 | 0 | 9.68% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | S | Common Stock | 1791 | $0.63 | 52,388.0000 | 0 | 3.31% | 0.00% |
| Jan. 14, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | S | Common Stock | 1007 | $0.66 | 49,396.0000 | 0 | 2.00% | 0.00% |
| Jan. 13, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 2646 | $0.00 | 5,292.0000 | 0 | 33.33% | 0.00% |
| Jan. 13, 2025 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 2646 | $0.00 | 50,403.0000 | 0 | 5.54% | 0.00% |
| Oct. 3, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | S | Common Stock | 3361 | $1.96 | 47,757.0000 | 0 | 6.57% | 0.00% |
| Oct. 1, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 30000 | $0.00 | 55,973.0000 | 0 | 115.50% | 0.00% |
| Oct. 2, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | S | Common Stock | 4855 | $2.00 | 51,118.0000 | 0 | 8.67% | 0.00% |
| Oct. 1, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 30000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 833 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 13, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 2645 | $0.00 | 18,218.0000 | 0 | 16.98% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | A | Restricted Stock Unit | 16667 | $0.00 | 16,667.0000 | 0 | 9999.99% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 4519 | $0.00 | 4,519.0000 | 0 | 50.00% | 0.00% |
| Jan. 14, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 4783 | $0.00 | 9,566.0000 | 0 | 33.33% | 0.00% |
| Jan. 13, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Restricted Stock Unit | 2645 | $0.00 | 7,938.0000 | 0 | 24.99% | 0.00% |
| Jan. 16, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | S | Common Stock | 5025 | $2.71 | 23,328.0000 | 0 | 17.72% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 833 | $0.00 | 28,353.0000 | 0 | 3.03% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 4519 | $0.00 | 27,520.0000 | 0 | 19.65% | 0.00% |
| Jan. 14, 2024 | Mersana Therapeutics, Inc. | $MRSN | Mandelia Ashish | VP, Chief Accounting Officer | M | Common Stock | 4783 | $0.00 | 23,001.0000 | 0 | 26.25% | 0.00% |